Peptide vectors as drug carriers

Progress in Drug Research

Volumn 61, Issue , 2003, Pages 221-238

  Temsamani, Jamal ^a   Scherrmann, Jean Michel ^b  

^a Synt:em Parc Sci Georges Besse F   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery; Multidrug resistance; Peptide vector

Indexed keywords

DOXORUBICIN; DRUG CARRIER; LAMININ; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; PENETRATIN; PROTEGRIN; STREPTAVIDIN; SYNB1 PEPTIDE; SYNB3 PEPTIDE; TAT PEPTIDE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CARDIOTOXICITY; DISULFIDE BOND; DROSOPHILA; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; HELA CELL; HYDROPHOBICITY; INTERNALIZATION; LIPOPHILICITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0141508822     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8049-7_8     Document Type: Review

References (34)

1. Temsamani J, Rousselle, C, Rees AR, Scherrmann JM (2001) Vector-Mediated drug delivery to the brain. Expert Opin Biol Ther 1: 773-782
2. Derossi D, Chassaing G, Prochiantz A (1998) Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 8: 84-87
3. Langel U (ed) (2002) Cell penetrating peptides. Processes and applications. CRC Press, Boca Raton
4. Drin G, Rousselle C, Scherrmann JM, Rees AR, Temsamani J (2002) Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors. AAPS PharmSci 4, article 26
5. Harwig SS, Swiderek KM, Lee TD, Lehrer RI (1995) Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. J Pept Sci 1: 207-215
6. Drin G, Temsamani J (2002) Translocation of protegrin I through phospholipid membranes: role of peptide folding. Biochim Biophys Acta 1559: 160-170
7. Aumelas A, Mangoni M, Roumestand C, Chiche L, Despaux E, Grassy G, Calas B, Chavanieu A (1996) Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 237: 575-583
8. Mangoni ME, Aumelas A, Charnet P, Roumestand C, Chiche L, Despaux E, Grassy G, Calas B, Chavanieu A (1996) Change in membrane permeability induced by protegrin 1: implication of disulphide bridges for pore formation. FEBS Lett 383: 93-98
9. Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL (1999) Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta 1420: 23-29
10. Prochiantz A (1999) Homeodomain-derived peptides. In and out of the cells. Ann NY Acad Sci 886: 172-179
11. Vivès E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017
12. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57: 679-686
13. Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B, Scherrmann JM, Temsamani J (2001) Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 296: 124-131
14. Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, Temsamani J (2001) Doxorubicin-peptide conjugates overcome multidrug resistance. Anti-Cancer Drugs 12: 107-116
15. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427
16. Tsuji A (1998) P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit 20: 588-590
17. Bolton SJ, Jones DN, Darker JG, Eggleston DS, Hunter AJ, Walsh FS (2000) Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur J Neurosci 12: 2847-2855
18. Rousselle C, Clair P, Temsamani J, Scherrmann JM (2002) Improved Brain Delivery of Benzylpenicillin with a Peptide-Vector-Mediated Strategy. J Drug Target 10: 309-315
19. Norrby, R. (1980) Penetration of antimicrobial agents into cerebrospinal fluid: Pharmacokinetic and clinical aspects. In: JH Wood (ed): Neurobiology of Cerebrospinal Fluid. Plenum Press, New York, 449-463
20. 14C-penicillin from cerebrospinal fluid to blood. J Pharm Sci 58: 1106-1109
21. 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci 66: 495-502
22. Kalenikova EI, Dmitrieva OF, Korobov NV, Zhukovskii SV, Tishchenko VA (1988) Pharmacokinetics of dalargin. Vopr Med Khim 34: 75-83
23. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674: 171-174
24. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87: 1305-1307
25. Schwarze SR, Ho A, VoceroAkbani A, Dowdy SF (1999) In vivo protein transduction of a biologically active protein in the mouse. Science 285: 1569-1572
26. Hardebo JE, Kahrstrom J (1985) Endothelial negative surface charge areas, and blood-brain barrier function. Acta Physiol Scand 125: 495-499
27. Vordbrodt AW (1988) Ultrastructural cytochemistry of blood-brain barrier endothelia. Prog Histochem Cytochem 18: 1-99
28. Bar RS, DeRose A, Sandra A, Peacock ML, Owen WG (1983) Insulin binding to microvascular endothelium of intact heart: A kinetic and morphometric analysis. Am J Physiol 244:477-482
29. Virgintino D, Monaghan P, Robertson D, Errede M, Bertossi M, Ambrosi G, Roncali L (1997) An immunohistochemical and morphometric study on astrocytes and microvasculature in the human cerebral cortex. Histochem J 29: 655-660
30. Bertossi M, Virgintino D, Maiorano E, Occhiogrosso M, Roncali L (1997) Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 21: 41-49
31. Walus LR, Pardridge WM, Starzyk RM, Friden PM (1996) Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. J Pharmacol Exp Ther 277: 1067-1075
32. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM (1991) Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88: 4771-4775
33. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm AC (1993) Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259: 373-377
34. Letvin NL, Chalifoux LV, Reimann KA, Ritz J, Schlossman SF, Lambert JM (1986) In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest 77: 977-984